Min Lu1, Zhuo Liu2, Bo Li2, Gang Wang2, Dechuan Li2, Yuping Zhu3. 1. Department of Medical Ultrasonics, Zhejiang Cancer Hospital, Hangzhou, 310002, Zhejiang Province, China. 2. Department of Colorectal Surgery, Zhejiang Cancer Hospital, 1st East Banshan Road, Hangzhou, 310002, Zhejiang Province, China. 3. Department of Colorectal Surgery, Zhejiang Cancer Hospital, 1st East Banshan Road, Hangzhou, 310002, Zhejiang Province, China. zhuyuping1314@yeah.net.
Abstract
BACKGROUND: Long non-coding RNAs (lncRNAs) have been shown to have crucial regulatory roles in human cancer biology. LncRNA PANDAR is a novel identified lncRNA that was previously reported to be increased in various cancers; however, its effect in colorectal cancer (CRC) remains unknown. The aim of this study was to explore the expression and role of lncRNA PANDAR in CRC. METHODS: The expression of lncRNA PANDAR was examined in CRC samples and cell lines by qRT-PCR. Kaplan-Meier survival analysis and univariate and multivariate Cox proportional hazards model were performed to evaluate the clinical and prognostic significance of lncRNA PANDAR in CRC patients. Furthermore, the biological function of lncRNA PANDAR on tumor cell growth, apoptosis and mobility was investigated through CCK-8, soft agar colony formation, flow cytometry, transwell migration and invasion assays in vitro. The potential mechanism of lncRNA PANDAR was demonstrated by Western blot and qRT-PCR. RESULTS: The expression level of PANDAR was higher in CRC tissues and cells compared to adjacent non-tumor tissues and normal colonic epithelial cells. Patients with high PANDAR expression level had poorer overall survival than those with low PANDAR expression. Moreover, multivariate analysis showed that the status of PANDAR expression was an independent prognostic indicator for CRC. Knockdown of PANDAR could inhibit cell growth, migration and invasion, arrest cell cycle as well as induce apoptosis of CRC cells in vitro study. In addition, PANDAR could affect epithelial-mesenchymal transition through inhibiting N-cadherin, vimentin, β-catenin, Snail and Twist expression and increasing the expression levels of E-cadherin. CONCLUSION: Our data suggested that lncRNA PANDAR was a novel molecule involved in CRC progression, which provided a potential prognostic biomarker and therapeutic target for new therapies in patients with CRC.
BACKGROUND: Long non-coding RNAs (lncRNAs) have been shown to have crucial regulatory roles in humancancer biology. LncRNA PANDAR is a novel identified lncRNA that was previously reported to be increased in various cancers; however, its effect in colorectal cancer (CRC) remains unknown. The aim of this study was to explore the expression and role of lncRNA PANDAR in CRC. METHODS: The expression of lncRNA PANDAR was examined in CRC samples and cell lines by qRT-PCR. Kaplan-Meier survival analysis and univariate and multivariate Cox proportional hazards model were performed to evaluate the clinical and prognostic significance of lncRNA PANDAR in CRC patients. Furthermore, the biological function of lncRNA PANDAR on tumor cell growth, apoptosis and mobility was investigated through CCK-8, soft agar colony formation, flow cytometry, transwell migration and invasion assays in vitro. The potential mechanism of lncRNA PANDAR was demonstrated by Western blot and qRT-PCR. RESULTS: The expression level of PANDAR was higher in CRC tissues and cells compared to adjacent non-tumor tissues and normal colonic epithelial cells. Patients with high PANDAR expression level had poorer overall survival than those with low PANDAR expression. Moreover, multivariate analysis showed that the status of PANDAR expression was an independent prognostic indicator for CRC. Knockdown of PANDAR could inhibit cell growth, migration and invasion, arrest cell cycle as well as induce apoptosis of CRC cells in vitro study. In addition, PANDAR could affect epithelial-mesenchymal transition through inhibiting N-cadherin, vimentin, β-catenin, Snail and Twist expression and increasing the expression levels of E-cadherin. CONCLUSION: Our data suggested that lncRNA PANDAR was a novel molecule involved in CRC progression, which provided a potential prognostic biomarker and therapeutic target for new therapies in patients with CRC.
Entities:
Keywords:
Colorectal cancer; Long non-coding RNA; PANDAR; Prognosis
Authors: Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Jonathan Krell; Adam E Frampton; Reza Mirnezami; Victoria Harding; Alex De Giorgio; Laura Roca Alonso; Patrizia Cohen; Silvia Ottaviani; Teresa Colombo; Jimmy Jacob; Loredana Pellegrino; Gordon Buchanan; Justin Stebbing; Leandro Castellano Journal: PLoS One Date: 2014-06-13 Impact factor: 3.240
Authors: Maria Lee; Hee Jung Kim; Sang Wun Kim; Sun-Ae Park; Kyung-Hee Chun; Nam Hoon Cho; Yong Sang Song; Young Tae Kim Journal: Oncotarget Date: 2016-07-12